Predict your next investment

Venture Capital
altitudelsv.com

See what CB Insights has to offer

Investments

50

Portfolio Exits

18

Funds

5

About Altitude Life Science Ventures

Altitude Life Science Ventures seeks opportunities to invest in early stage life science companies within markets with significant demand and growth potential, and then backs the highest-quality teams in those markets to build defensible, strong, and long-term businesses. At Altitude, our scope of investment opportunities extends beyond prescription drugs to any commercial application of proprietary technology that originates from a key advance in biology or chemistry.

Altitude Life Science Ventures Headquarter Location

1014 Market St., Suite 200

Kirkland, Washington, 98033,

United States

650-843-5000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Altitude Life Science Ventures News

Tessera raises more than $300 million in Series C financing

Apr 21, 2022

US biotech firm Tessera Therapeutics, which is pioneering a new approach in genetic medicine known as GENE WRITING technology, has raised over $300 million in Series C financing. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Alaska Permanent Fund Corporation; Altitude Life Science Ventures; ARTIS Ventures; Cormorant Asset Management; Tessera’s founder, Flagship Pioneering; Hanwha Impact Partners; Longevity… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Altitude Life Science Ventures Investments

50 Investments

Altitude Life Science Ventures has made 50 investments. Their latest investment was in Tessera Therapeutics as part of their Series C on April 4, 2022.

CBI Logo

Altitude Life Science Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/19/2022

Series C

Tessera Therapeutics

$300M

No

3

4/11/2022

Series A

Ansa Biotechnologies

$68M

Yes

4

11/18/2021

Series B

Generate Biomedicines

$370M

Yes

15

10/26/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/28/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/19/2022

4/11/2022

11/18/2021

10/26/2021

7/28/2021

Round

Series C

Series A

Series B

Series A

Series B

Company

Tessera Therapeutics

Ansa Biotechnologies

Generate Biomedicines

Subscribe to see more

Subscribe to see more

Amount

$300M

$68M

$370M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

4

15

10

10

Altitude Life Science Ventures Portfolio Exits

18 Portfolio Exits

Altitude Life Science Ventures has 18 portfolio exits. Their latest portfolio exit was DiCE Molecules Holdings on September 15, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/15/2021

IPO

$99M

Public

3

8/5/2021

Acquired

$99M

13

7/20/2021

Acquired

$99M

7

6/17/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/27/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/15/2021

8/5/2021

7/20/2021

6/17/2021

5/27/2021

Exit

IPO

Acquired

Acquired

IPO

Acq - Pending

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

3

13

7

10

10

Altitude Life Science Ventures Fund History

5 Fund Histories

Altitude Life Science Ventures has 5 funds, including Altitude Life Science Ventures Side Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/22/2019

Altitude Life Science Ventures Side Fund III

$50M

1

3/19/2018

Altitude Life Science Ventures III

10

4/28/2015

Altitude Life Science Ventures II

$99M

10

4/27/2015

Altitude Life Science Ventures Fund II

10

Altitude Life Science Ventures Fund IV

10

Closing Date

1/22/2019

3/19/2018

4/28/2015

4/27/2015

Fund

Altitude Life Science Ventures Side Fund III

Altitude Life Science Ventures III

Altitude Life Science Ventures II

Altitude Life Science Ventures Fund II

Altitude Life Science Ventures Fund IV

Fund Type

Status

Amount

$50M

$99M

Sources

1

10

10

10

10

Altitude Life Science Ventures Team

1 Team Member

Altitude Life Science Ventures has 1 team member, including current Founder, David Maki.

Name

Work History

Title

Status

David Maki

Founder

Current

Name

David Maki

Work History

Title

Founder

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.